Torsades de pointes caused by Mibefradil

European Journal of Heart Failure

Volumn 3, Issue 5, 2001, Pages 627-630

  Gläser, Sven ^a   Steinbach, Michaela ^a   Opitz, Christian ^a   Wruck, Ullrich ^a   Kleber, Franz X ^a  

^a UNFALLKRANKENHAUS BERLIN   (Germany)

Author keywords

Calcium channel blocker; Mibefradil; Torsades de pointes; Ventricular tachycardias

Indexed keywords

ALLOPURINOL; CAPTOPRIL; DIGITOXIN; FUROSEMIDE; MIBEFRADIL; SPIRONOLACTONE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; HEART VENTRICLE TACHYCARDIA; HUMAN; PRIORITY JOURNAL; QT INTERVAL; THORAX RADIOGRAPHY; TORSADE DES POINTES;

AGED; ANGINA PECTORIS; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; HYPERTENSION; LONG QT SYNDROME; MIBEFRADIL; TACHYCARDIA, VENTRICULAR; TORSADES DE POINTES;

EID: 0035740714     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(01)00159-3     Document Type: Article

References (10)

1. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications
2. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist
3. Mibefradil: A new class of calciumchannel antagonists
4. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967)
5. Dose-response characteristics of mibefradil, a novel calcium antagonist in the treatment of essential hypertension
6. FDA warns on calcium-channel blocker
7. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist
8. 2+ release in cultured rat cardiac fibroblasts and human platelets
9. + channels involved in long QT syndroms, are targets for calcium channel blockers
10. + channels Ikr and Iks